A recent report by EURL-ECVAM on alternative methods ( Zuang et a

A recent report by EURL-ECVAM on alternative methods ( Zuang et al., 2013) also provided an update on the regulatory validation of several in vitro assays. To date EpiOcular EIT has passed initial validation studies ( Zuang et al., 2013) and guidelines are currently being drafted by the OECD (2014b). The HET and IRE have been rejected by ICCVAM while the EURL-ECVAM has requested further optimization of the test protocol. We have presented an overview of current practices

in ocular toxicity selleck screening library testing. While progress has been made in developing a range of alternative techniques to in vivo testing, further progress is required to reduce the dependency of toxicity testing on live animals. Among the issues that need to be addressed by regulatory bodies is whether Draize testing should still be considered as the “gold standard” and whether results obtained from such testing used to validate or evaluate alternative tests. In order to advance alternative testing methodologies, there needs to be active engagement and dialog between scientific and regulatory communities. The authors declare that there are no conflicts of interest. Funding from EPSRC Engineering, Tissue Engineering and Regenerative

Medicine Fellowship (E-TERM, Grant number: EP/1017801/1) and the University of Nottingham HERMES Fellowship (Grant number: 13b/I9) is gratefully acknowledged. “
“The following corrections should be read in this check details article:

BMDL(ID)s in Table 1: • % deformed sperm heads: is 143,867 ng/g lipid, not 2968 as printed; BMDL of PROD in males (Table 1 and text, Section 3.9) is 0.5 mg/kg bw, not 1.3. In Table 1, footnote ‘a’ also applies to the CYP1A2 mRNA in females. In Fig. 4B, horizontal axis units should be read as log10 ng pentaBDE per mg liver lipid instead of per 10 μg liver lipid. In the text, Section 2.10, the sentence explaining conversion of external to internal doses using a regression equation should be ignored. In Section 3.9, the last sentence of the second paragraph should read: The effect Tolmetin size in the highest dosis showed a decreasing trend for some of these drug metabolism related parameters (Supplementary Table 9). These corrections do not affect the interpretations and conclusions of the paper. “
“The author regrets that the following error has inadvertently appeared in the above article. In Table 1 on page 82, in the first column, in the ninth line from the top, the term should have read ‘genistein’ instead of ‘genestin’. Please see below the corrected Table 1. “
“This article has been removed: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy). This article has been removed at the request of the Author. This abstract was inadvertently published in the journal when the authors had requested that it should not.

Comments are closed.